The pharmaceutical industry stands at crossroads with traditional business models becoming obsolete in today’s heavily disrupted marketplace. Although it may be too late to halt the decline of the traditional model by incremental adjustments or by steady evolution, it is certainly not too late to rethink how pharmaceutical companies can adapt and thrive in the face of shifting payer attitudes and patient empowerment.
A cursory glance at the current pharmaceutical industry might imply that all is well. However, there are two seismic shifts that are expected to disturb the industry status quo – the downward pressure on drug pricing and the